ObjectiveTo determine feasibility, compliance, long-term survival, and disease control rates in the intensification regimen for advanced resectable hypopharyngeal carcinoma.DesignProspective, nonrandomized, controlled phase 2 trial with a median follow-up period of 89 months (range, 3.4-140.0 months).SettingCancer center at a state university.PatientsThirty-two patients (age range, 44-79 years; median age, 59 years) with advanced (69% stage IV, 31% stage III) resectable hypopharyngeal carcinoma.InterventionsCombination of surgery, radiation therapy, and chemotherapy (cisplatin and paclitaxel) along with intraoperative radiation therapy.Main Outcome MeasuresCompliance, long-term survival, and locoregional and systemic disease control rates and functional outcome.ResultsThe protocol compliance rate was 62% (20 of 32 patients), and the overall 5-year survival rate was 56%. Local recurrence occurred in 3 patients (9%). The systemic disease control rate was 91% (29 of 32 patients). Total laryngectomy was required in 15 patients (47%); preservation of the larynx was possible in 17 patients (53%). Only 3 (13%) of 6 patients were percutaneous endoscopic gastrostomy tube dependent in the long-term follow-up.ConclusionsThe intensification regimen described in this study accomplished excellent long-term survival and disease control rates in patients with advanced resectable hypopharyngeal carcinoma. The future plan is to proceed with a phase 3 trial if the single-institutional experience at The Ohio State University can be duplicated in a multi-institutional phase 2 study.Cancers of the head and neck represent 6.6% of all cancers in the body. The larynx, oral cavity, thyroid, and oropharynx, respectively, are the most common sites for head and neck cancer. Only 4.3% of head and neck cancers originate from the hypopharynx. Rarity, alone, creates significant methodological problems with data collection.Unfortunately, 77%of hypopharyngeal cancers (HPCs) are stage III/IV at the time of diagnosis. Although surgery, radiation therapy, or a combination of both has been the treatment of choice in HPC in the last decades, there has been no significant improvement in survival. Hypopharyngeal cancers still have the worst prognosis of all malignant neoplasms of the upper aerodigestive tract, with 5-year survival rates ranging from 19% to 31%.Clinical studies have provided encouraging results demonstrating enhanced ability to control locoregional disease with concurrent chemoradiotherapy in advanced resectable head and neck cancer. These studies have demonstrated improvement in locoregional control, and some have shown survival improvement in certain head and neck cancer subpopulations as well.In a more recent article, Hanna et alreported the efficacy of intensive chemoradiotherapy as a primary modality for organ preservation in patients with advanced squamous cell carcinoma of the head and neck. Despite the improvement in the overall 3-year survival rate (57%), the rate of distant metastasis was still high (14%) and accounted for almost 40% of all treatment failures.Recent encouraging results of multimodal treatments motivated us to initiate a series of pilot studies evaluating a therapeutic regimen designed to improve survival and compliance in previously untreated resectable advanced-stage (III and IV) squamous cell carcinoma arising in the oral cavity, oropharynx, and hypopharynx.A combination of surgery, radiation therapy, and chemotherapy together with intraoperative radiation therapy (IORT) was designed as a regimen with the intent to intensify therapy at the primary tumor site, regional neck nodes, and distant sites, while improving patient compliance. A series of articles reported the results of modifications in the regimen to achieve the stated goals.The present article summarizes the long-term disease control, survival, and functional outcome results after multimodal treatment for resectable advanced-stage HPC.METHODSThe patients were recruited from the Department of Otolaryngology–Head and Neck Surgery, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Comprehensive Cancer Center, The Ohio State University, Columbus. The investigational protocol was reviewed and approved by the institutional review board of The Ohio State University and the Scientific Review Committee of the Comprehensive Cancer Center. Eligible patients had previously untreated resectable SCC of the hypopharynx. The patients with resectable disease included those whose preoperative assessment determined the probability of all clinically detectable disease being surgically removed with negative histologic margins of resection. Eligible patients also must have had stage III or stage IV disease according to the American Joint Committee on Cancer (1997) and no distant metastases. A Karnofsky performance index of 60 or higher; adequate bone marrow function (platelet count >100 × 103/μL and absolute neutrophil count >2.0 × 103/μL); creatinine clearance greater than 1.0 mL/s (>60 mL/min); and adequate hepatic function (bilirubin <1.8 mg/dL [<31 μmol/L] and serum transaminase values 4 times the upper limit) were required. Written informed consent was obtained from all patients before the initiation of therapy. Patients with prior malignant neoplasms were excluded unless they were disease free for 5 years, had adequately treated basal or squamous cell skin cancers, or had in situ cervical cancer (because of the excellent prognosis associated with these limited cancers). Patients with a history of cardiac disease were cleared for treatment by the medical oncologist. In general, patients with prior bradyarrhythmias, atrioventricular conduction defects, or marginal cardiac function were eligible but underwent cardiac monitoring during treatment. During the course of 3 phase 2 trials evaluating the intensification regimen, there were 32 patients with hypopharyngeal primary tumors.The most recently applied intensification regimen (Table 1) is as follows: Perioperatively (days 1-4), the patients were given a slightly accelerated hyperfractionated boost of external beam radiotherapy consisting of 9.1 Gy with 6-MV x-rays delivered to the primary tumor and clinically involved nodes (excluding the spinal cord). The external beam radiotherapy was divided into 7 twice-daily treatments of 1.3 Gy, with an interfraction interval of at least 6 hours. Concurrent cisplatin chemotherapy (30 mg/m2per day) was delivered intravenously on days 1 to 3. Patients were hydrated intravenously with 1 L of 0.45% sodium chloride with 10 mEq of potassium chloride, 3 g of magnesium sulfate, and 40 g of mannitol for 2 hours before cisplatin therapy. Surgical resection and IORT to the site of closest surgical margin were performed on day 4. For patients with negative surgical margins (as determined by intraoperative frozen-section pathologic analysis), an intraoperative dose of 7.5 Gy was delivered with 6-MeV electrons (prescribed to the 90% isodose).Table 1. Intensification RegimenTreatmentPrestudyDays 1-3Day 4Day 10Day 31Day 32SurgeryTriple endoscopy and biopsy, gastrostomy tube placement. . .Surgical resection. . .. . .. . .IORT. . .. . .Boost to area of close (7.5 Gy) or positive margins (10.0 Gy) with 6-MeV electrons (90% isodose) or HDRB at 0.5-cm depth. . .. . .. . .EBRT. . .Off-cord boost 9.2 Gy over 7 twice-daily treatments (1.3-Gy fractions with 6-MV photons)Off-cord boost 9.2 Gy over 7 twice-daily treatments (1.3-Gy fractions with 6-MV photons). . .. . .Begin 40 Gy/20 fractions, 6-MV photons to primary and nodal areas, and 45 Gy/20 fractions, 6-MV photons to lower neck and bilateral supraclavicular areas; if positive node >3 cm, electron boost to bilateral posterior neck area (10 Gy/5 fractions)Cisplatin. . .30 mg/m2daily for 3 d. . .. . .30 mg/m2daily for 3 d every 3 wk, 2 cycles total. . .Paclitaxel. . .. . .. . .45 mg/m2over 3 h weekly, 9 cycles total. . .. . .Abbreviations: EBRT, external beam radiotherapy; HDRB, high-dose rate brachytherapy; IORT, intraoperative radiotherapy.On day 10, the patients began receiving weekly 3-hour infusions of paclitaxel (45 mg/m2). All patients were premedicated with dexamethasone (20 mg administered orally at 12 and 6 hours before the beginning of paclitaxel infusion or 20 mg administered intravenously 30 minutes before paclitaxel infusion). The patients received 300 mg of cimetidine hydrochloride intravenously and 50 mg of diphenhydramine hydrochloride intravenously 30 minutes before paclitaxel therapy. Subsequent courses of the same dose of paclitaxel were given weekly on an outpatient basis on days 17, 24, 31, 38, 45, 52, 59, and 66, for a total of 9 courses of paclitaxel therapy.On day 31, after intravenous hydration, patients received a second course of cisplatin (30 mg/m2daily for 3 days). On day 32, patients underwent external beam radiotherapy with 6-MV x-rays (an additional 40 Gy delivered in 20 treatments to the primary tumor site and regional draining lymph nodes and 45 Gy delivered in 20 treatments to the lower neck and bilateral supraclavicular areas). Parallel opposed upper neck fields were prescribed to the midline, and the lower neck/supraclavicular field was prescribed to the 100% isodose. If a histologically positive node larger than 3 cm was present, bilateral posterior neck electron boosts of 10 Gy (at 100% isodose) were delivered in 5 treatments. The electron energy was chosen to limit the spinal cord dose to less than 45 Gy (total dose). On day 52, the third course of cisplatin (30 mg/m2daily for 3 days) was administered (with hydration as previously described).Recombinant human granulocyte-colony–stimulating factor was administered at the discretion of the medical oncologist (eg, for neutropenic fever). Prophylactic antibiotic and antifungal therapy consisting of oral ciprofloxacin (500 mg twice daily) and oral fluconazole (100 mg/d) was administered to patients who developed an absolute neutrophil count of less than 0.5 × 103/μL and continued until the absolute neutrophil count was above 1.5 × 103/μL. Radiotherapy was delayed when the absolute neutrophil count was less than 0.5 × 103/μL and continued when it was greater than 0.5 × 103/μL. If the absolute neutrophil count was less than 1.5 × 103/μL, then chemotherapy was delayed until it rose above 1.5 × 103/μL. If the delay in granulocyte recovery was 7 days or longer or if the patient had neutropenic fever, subsequent doses of paclitaxel were reduced to 30 mg/m2(33% dose reduction). Paclitaxel is used to improve the control of distant metastases and is administered as a 3-hour infusion at a dose of 45 mg/m2for 9 weeks.RESULTSThe study population included 27 men and 5 women with squamous cell carcinoma of the hypopharynx (Table 2). Three of the male patients and 1 of the female patients were African American. The remaining patients were white. Their ages ranged from 44 to 79 years, with a median of 59 years. Twenty-eight patients had cancer of the pyriform sinus; 3 had cancer of the posterior pharyngeal wall; and 1 had cancer of the postcricoid region. Although 1 patient in the study group had T1 disease and 8 patients had T2 disease, overall 10 patients (31%) had stage III disease at presentation and the rest (22 [69%]) had stage IV disease (Table 3).Table 2. Patient PopulationVariableValue*Sex Male27 (84) Female5 (16)Race White28 (88) African American4 (12)Age, y Range44-79 Median59 Tumor sitePyriform sinus28 (88)Posterior pharyngeal wall3 (9)Postcricoid region1 (3)Overall stage III10 (31) IV22 (69)Grade Poorly differentiated9 (28) Moderately differentiated21 (66) Well differentiated2 (6)*Values other than age are expressed as number (percentage).Table 3. T and N DistributionTumorNodal StatusTotal012a2b2c31. . .. . .1. . .. . .. . .1213. . .211835. . .143114433. . .2. . .19Total96284332Resection of the primary tumor site ranged from partial pharyngectomty to total laryngopharyngectomy. Total pharyngectomy together with partial cervical esophagectomy, subtotal pharyngectomy, and partial pharyngectomy techniques were used in 3 patients (9%), 3 patients (9%), and 26 patients (82%), respectively. Total laryngectomy and partial laryngectomy was required in 15 patients (47%) and 11 patients (34%), respectively. The overall total or partial preservation of the larynx was achieved in 17 patients (53%). Thirty-two neck dissections were performed in 29 patients. The types of neck dissection included modified radical (n = 12), radical (n = 10), and extended radical (n = 8). Carotid artery invasion requiring carotid artery resection and replacement occurred in 2 patients.The pectoralis major musculocutaneuos flap, which was the most common pharyngeal and laryngopharyngeal reconstruction technique, was used 20 times in 18 patients (56%) (Table 4), including 16 patients with a total or partial laryngopharyngectomy and 2 with pharyngectomy defects. Carotid artery coverage in appropriate patients was accomplished with 10 dermal grafts, and acellular human dermis (Alloderm) was used in 1 patient.Table 4. Types of Reconstructive Techniques UsedReconstruction TypePatients, No. (%)Primary closure11 (35)Pectoralis major myocutaneous flap16 (50)Bilateral pectoralis major myocutaneous flap2 (6)Deltopectoral flap1 (3)Radial forearm free flap1 (3)Skin graft1 (3)Total32 (100)The rate of protocol compliance (receiving all courses of treatment per protocol) was 62% (20 of 32 patients). Noncompliance occurred in 12 cases, 5 of which were patient directed. Four patients could not receive further chemotherapy because of heart attack, elevated levels of serum urea nitrogen and/or creatinine (2 patients), and peripheral neuropathy. Two patients experienced stroke, and 1 patient died of sepsis during the treatment.The median overall follow-up period was 89 months (range, 3.4-140.0 months). The overall 5-year survival rate was 56% (Figure). Only 4 (12%) of the 32 patients died of disease. The 5-year disease-free survival rate was 53%. Two patients died of primary lung cancer during the 12th and the 96th month of follow-up. The other causes of the deaths among the patients without disease were acute renal failure, respiratory failure, cerbrovascular accident, gall bladder surgery complication, ruptured abdominal aortic aneurysm, and unknown etiology.Figure.Long-term overall survival.The locoregional and systemic disease control rates were both 91% (29 of 32 patients). All 3 distant metastases involved the lungs. Local recurrence occurred simultaneously with distant metastasis in 1 patient who had refused IORT and postoperative chemoradiotherapy.Preservation of the larynx was possible in 17 patients (53%). Tracheoesophageal puncture and voice prosthesis were used in 13 (87%) of the 15 patients who underwent total laryngectomy. Six (26%) of 23 patients with the minimum follow-up period of 24 months experienced dysphagia, and only 3 (13%) of these 6 patients needed a permanent percutaneous endoscopic gastrostomy tube. All the patients who underwent surgical procedures for larynx preservation could successfully be decannulated, and none of them needed a permanent tracheostomy tube.COMMENTHypopharyngeal carcinoma is a rare disease, representing only 4.3% of all malignant neoplasms in the head and neck.It still produces the worst prognosis among head and neck cancers. Regardless of treatment modality, the prognosis for advanced HPC is extremely poor. Surgery, radiation therapy, or a combination of both has been the treatment of choice for HPC in the last decades. With standard primary radiation therapy and salvage surgery, the overall 5-year survival rate is approximately 20%.Chemotherapy was added to the treatment regimen in only 18% of HPC cases.The results of a large, well-conducted meta-analysis by Pignon et al,who looked at the effects of chemotherapy added to locoregional treatment in head and neck cancers, suggested that a significant survival benefit (8%) was associated with concomitant chemoradiation schedules. On the other hand, in a recent study, even with combined definitive chemoradiotherapy, the overall 5-year survival rate was still 15% in cases of HPC.Pinheiro et alevaluated the use of IORT as an adjuvant modality in the treatment of advanced cancer of the head and neck and skull base and found that it is safe at a dose of 12.5 Gy and that it improves tumor control and survival for patients who are likely to have microscopic residual disease in sites that are difficult to resect, such as the skull base. The safety and effectiveness of IORT have also been demonstrated in the management of advanced cervical metastasis.Although IORT is still not easily found in all tertiary medical centers, part of the success in disease control and survival in the intensification regimen is contributed by IORT.The effectiveness of both paclitaxel and cisplatin therapy for head and neck cancer is very well known. Eckardt et aldemonstrated impressive clinical and pathologic response rates (58% complete pathologic response) with concurrent weekly paclitaxel-carboplatin therapy and radiotherapy as a preoperative treatment modality in advanced oral and oropharyngeal cancer. In the intensification regimen, along with weekly preoperative chemoradiotherapy with cisplatin, 9 weeks of paclitaxel therapy was added to 2 more postoperative cycles of cisplatin.Although Cooper et alfound that concurrent postoperative chemoradiotherapy significantly improves the rate of local and regional control (82% in 2 years) and disease-free survival (78% in 2 years) in high-risk patients with resected head and neck cancer, the combination of chemotherapy was associated with a substantial increase in adverse effects. Bernier et alalso supported these findings in a recent study of advanced-stage head and neck cancer, even though the overall 5-year survival rates among the patients who received postoperative adjuvant chemoradiotherapy and radiotherapy alone were 53% and 40%, respectively. The intensification regimen in our study resulted in a protocol compliance rate (ie, patients receiving all courses of treatment per protocol) of 62%, and only 1 patient died (of sepsis) during the treatment, while achieving overall survival rates of 67% at 3 years and 56% at 5 years.Beauvillain et alcompared long-term survival and local disease control rates in cases of advanced resectable HPC in the treatment arm of neoadjuvant chemotherapy-surgery-radiotherapy (arm A) and neoadjuvant chemotherapy and radiotherapy alone without surgery (arm B). After a mean follow-up of 92 months, survival was statistically better in arm A (overall 5-year survival rate, 37%; median survival, 40 months) than in arm B (overall 5-year survival rate, 19%; median survival, 20 months) because of a better local control rate (63% vs 39%). On the other hand, the same successful results could not be demonstrated in other studies,and the 5-year survival rates were similar in the nonsurgical and the surgical groups. Also, the larynx preservation rate was only 35%.The larynx preservation rate in our study was 53%, and 17 (87%) of the patients who underwent laryngectomy were successfully treated with a voice prosthesis. Only 3 (26%) of the patients experienced dysphagia, and 6 (13%) needed a permanent percutaneous endoscopic gastrostomy tube.Distant metastases remain a major cause of death in patients with advanced HPC.The local and distant disease control rates in our patient population were excellent: 91%. All 3 distant metastasis sites were the lungs. Unfortunately, 2 other patients developed a second primary lung cancer. Therefore, the prevention and treatment of second primary tumors are going to be major concerns in the future.The intensification regimen described herein has been successfully used in the treatment of advanced resectable head and neck cancers for 12 years. Although it requires interdisciplinary cooperation and specialized radiotherapeutic technologies such as IORT, our goal is to duplicate these encouraging single-institutional phase 2 results in multi-institutional cooperative studies and then to proceed with a phase 3 trial if the single-institutional experience at The Ohio State University can be duplicated in a multi-institutional phase 2 study.Correspondence:Enver Ozer, MD, Department of Otolaryngology–Head and Neck Surgery, The Ohio State University, 456 W 10th Ave, Room 4110, Columbus, OH 43210 (email@example.com).Submitted for Publication:January 14, 2005; final revision received August 10, 2005; accepted October 19, 2005.Financial Disclosure:None.Funding/Support:This study was supported in part by grant P30 CA16058 from the National Cancer Institute, Bethesda, Md; The Ohio State University Comprehensive Cancer Center Head and Neck Oncology Group; and the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.REFERENCESHTHoffmanLHKarnellGFFunkRARobinsonHRMenckThe National Cancer Data Base report on cancer of the head and neck.Arch Otolaryngol Head Neck Surg19981249519629738803HTHoffmanLHKarnellJPShahHypopharyngeal cancer patient care evaluation.Laryngoscope1997107100510179260999LVJohansenCGrauJOvergaardHypopharyngeal squamous cell carcinoma: treatment results in 138 consecutively admitted patients.Acta Oncol20003952953611041117KKFuCombined-modality therapy for head and neck cancer.Oncology199711178117969436185MAl-SarrafTFPajakRWByhardtJJBeitlerMMSalterJSCooperPostoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24.Int J Radiat Oncol Biol Phys1997377777829128951EHannaMAlexiouJMorganIntensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.Arch Otolaryngol Head Neck Surg200413086186715262764DESchullerJCGreculaRAGahbauerIntensified regimen for advanced head and neck squamous cell carcinomas.Arch Otolaryngol Head Neck Surg19971231391449046279JCGreculaDESchullerCARhoadesIntensification regimen 2 for advanced head and neck squamous cell carcinomas.Arch Otolaryngol Head Neck Surg19991251313131810604408JCGreculaRESmithCARhoadesInduction paclitaxel in previously untreated, resectable, advanced squamous cell carcinomas of the head and neck.Cancer2000892587259611135220DESchullerGLaramoreMAl-SarrafJJacobsTFPajakCombined therapy for resectable head and neck cancer: a phase 3 intergroup study.Arch Otolaryngol Head Neck Surg19891153643682644954DESchullerJCGreculaAAgrawalMultimodal intensification therapy for previously untreated advanced resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx.Cancer2002943169317812115349JPPignonJBourhisCDomengeLDesigneChemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data: MACH-NC Collaborative Group.Lancet200035594995510768432MJZelefskyDHKrausDGPfisterCombined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer.Head Neck1996184054118864731ADPinheiroRLFooteTVMcCaffreyIntraoperative radiotherapy for head and neck and skull base cancer.Head Neck20032521722612599289SBFreemanRCHamakerWRRateManagement of advanced cervical metastasis using intraoperative radiotherapy.Laryngoscope19951055755787769938AEckardtDRadesVRudatProspective phase II study of neoadjuvant radiochemotherapy in advanced operable carcinoma of the mouth cavity: 3-year outcome [in German].Mund Kiefer Gesichtschir2002611712112017874JSCooperTFPajakAAForastierePostoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.N Engl J Med20043501937194415128893JBernierCDomengeMOzsahinPostoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.N Engl J Med20043501945195215128894CBeauvillainMMaheSBourdinFinal results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas.Laryngoscope19971076486539149168JLLefebvreDChevalierB,LuboinskiLarynx reservation in pyriform sinus cancer: preliminary results of a European Organisation for Research and Treatment of Cancer phase III trial: EORTC Head and Neck Cancer Cooperative Group.J Natl Cancer Inst199638908998656441
JAMA Otolaryngology - Head & Neck Surgery – American Medical Association
Published: Apr 1, 2006
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera